Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Pharma Stock to Buy According to Hedge Funds?
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
11 Best Pharma Stocks to Buy According to Hedge Funds
The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.
Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners 2025 Global Healthcare Conference Call Transcript
Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN) Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET ...
Le Lézard3d
REGN LAWSUIT ALERT: The Gross Law Firm Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. . Shareholders who purchased ...
Jones Financial Companies Lllp Has $578,000 Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Jones Financial Companies Lllp increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) ...
FINAL REGN DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Regeneron Therapeutics, Inc. Investors to Join the Class Action Lawsuit
NEW YORK CITY, NY / ACCESS Newswire / March 9, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
1 Dividend Stock Down 30% to Buy and Hold for the Next Decade
Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...
JD Supra5d
First Circuit Decision Raises Bar on Anti-Kickback Statute-Premised Liability Under the False Claims Act
The United States Court of Appeals for the First Circuit recently joined the Sixth Circuit (2023) and Eighth Circuit (2022) ...
Why Is Regeneron (REGN) Down 4.1% Since Last Earnings Report?
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Life Sciences IP Review6d
Regeneron edges closer to Eylea market exclusivity amid biosimilar threats
New York biotech scores win as Fed Circ upholds preliminary injunction against Celltrion's biosimilar launch | Ruling follows ...
JD Supra7d
The Precedent: Federal Circuit Adds Clarity to Personal Jurisdiction and Obviousness-Type Double Patenting Analyses in Regeneron Pharms
In this edition of The Precedent, we outline the decision in Regeneron Pharms., Inc. v. Mylan Pharms. Inc. In Regeneron Pharms., Inc. v. Mylan ...
Regeneron's Injunction on Eylea Biosimilar Holds Up on Appeal
The Federal Circuit upheld a preliminary injunction blocking the launch of a Celltrion Inc. biosimilar version to Regeneron ...